Zhejiang Hisun Pharmaceutical Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Global Strategic Connections, LLC

Nestec S.a.

Zhejiang Hisun Chemical Co., Ltd.

Fudan University

Hisun Biopharmaceutical Co., Ltd.

Hua Bai

Xuyang Zhao

Dongliang Guan

Qifeng Zhu

Yuncai Zhang

Xiaojie Xu

Lei Chen

Xiaoyu Liu

Fuli Zhang

Xiaohe Zheng

Linghui Zheng

Weifeng Zhao

Zhongli Wang

Zhengjie Chen

Yutao Ma

Long Ling

Jun Gou

Feng Chen

Zhiqing Yang

Na Li

Jun Huang

Jidong Wang

Zhezhou Yang

Rusheng Bao

Zhenliang Chen

Yong Zhang

Yingqiu Wu

Hongyuan Wei

Chongjun Liu

Yongxiang Gong

Haibin Wang

Jinqing Zhong

Meihong Li

Ravindra Kumar Pandey

Jian Zhang

Hui Zhang

Jiang Li

Yanghui Guo

Changliang Dai

Weiwei Xu

Minghui Qi

Huijun Ren

Yun Teng

Junhui Zhou

Meidong Xu

Meiyi Mo

Zongyi Yang

Zhihui He

Lingping Wang

Peijie Yang

Lianiqing Jiang

Zigang Zhao

Chongyang Xu

Luyan Jiang

Wenming Zhu

Minghuang Hong

Yili Ding

Zhen Yu

Lifei Liu

Rentong Sun

Daoxin Chen

Lifeng Cai

Xufei Li

Dezhou Xu

Li Zhang

Xiaoming Wang

Zehua Zhong

Wei Zhou

Jinyao Chen

Guobin Ren

Yi Bu Li

Bin Liu

Pei Zhou

Quanhai Liu

Yi Li

Hegeng Wei

Yue Zhang

Jian Chai

Peng Sun

Fei Zheng

Maojian Gu

Hao Xu

Yihui Chen

Sheng Wang

Qingfeng Cai

Chunbo Yang

Nayan Patel

Manivannan Ethirajan

Hairong Luo

Meihua Xie

Yaping Wang

Meng Hu

Xuan Yang

Tianmin Zhu

Aiwen Deng

Jiatan Lin

Daochao Li

The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.

Pyrimidine derivative, method for preparing same and use thereof in medicine

The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description. 

The invention provides a construction method of spinosad heterologous expression strain, a spinosad heterologous expression strain obtained by the method and use thereof in preparing spinosad. The method utilizes a plurality of homologous recombination to replace the erythromycin synthetic gene cluster ofwith the spinosad synthetic gene cluster and the rhamnose synthetic gene cluster, such that theproduces spinosad.

Spinosad heterologous expression strain and construction method thereof and use

Provided are a() HS7522 and a method for preparing milbemycin A4 by culturing the. The() HS7522 of the present invention is deposited in 'China General Microbiological Culture Collection Center' with an accession number of CGMCC No. 9671 on Sep. 16, 2014.

Streptomyces and method for producing milbemycin A4 using same

The present invention relates to an acrylic acid derivative as shown in general formula (I), a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, the preparation method thereof, a pharmaceutical composition containing same, and the use thereof as therapeutic agents, in particular as selective estrogen receptor degraders (SERD), wherein the substituents of general formula (I) are the same as those defined in the description. 

Acrylic acid derivative, preparation method and use in medicine thereof

Intermediate compounds for the preparation of Praziquantel are provided. In particular, the intermediate compounds provided include a compound of formula (IV) and a compound of formula (V). Also provided are processes for preparing the intermediate compounds. Additionally, the raw materials are inexpensive and easy to obtain, the key intermediates are easy to prepare, and the total reaction yield and purity of the obtained target compound Praziquantel is high, so that industrialized mass production of Praziquantel using the intermediate compounds is easy to achieve.

Intermediate compounds for preparation of praziquantel and processes for preparing the intermediate compounds

Disclosed are a method for preparing a benzodioxole derivative (AD-35) shown by Formula (I) and an intermediate thereof. The method of the present invention involves: using piperic acid as a raw material; and performing bromination, esterification, cyanidation, cyclopropane lactamization, amide nitrogen alkylation, deprotection, piperidine nitrogen alkylation and salification to obtain the compound of Formula (I). The method has cheap and easily available start raw materials, short synthesis routes and simple operation, and is suitable for industrial production. 

Process for preparing AD-35

Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production. 

Method for preparing azetidinone compound and intermediate of azetidinone compound

The present invention relates to a recombinant microorganism expressing avermectin or analogs thereof and construction method thereof, and also relates to a method of producing avermectin or analogs thereof using the recombinant microorganism, and avermectin or analogs thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogs thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogs thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.

Recombinant microorganism expressing avermectin analogue and use thereof

A fidaxomicin purification method, comprising: fermentingsp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.

Fidaxomicin purification method

The present invention relates to a disaccharide intermediate and a synthesis method thereof, relates to the chemical pharmaceutical field, and more specifically relates to a method for preparing a disaccharide segment of a key intermediate for chemically synthesizing heparin and heparinoid compounds. Disclosed are a new disaccharide intermediate and three methods for synthesizing the disaccharide intermediate, that is, compounds of a formula (4) and glucopyranose protected by different anomeric carbon are made to react in the presence of an active agent, to obtain the disaccharide intermediate. According to the technical solutions of the present invention, synthetic raw materials are easy to obtain, have a mild reaction condition, and are suitable for industrialized production.

Disaccharide intermediate and synthesis method thereof

Provided are a() HS7523 and a method for preparing milbemycin A3 by culturing the. The() HS7523 is deposited in 'China General Microbiological Culture Collection Center' with an accession number of CGMCC No. 9672 on Sep. 16, 2014.

[object Object]

An indole derivative as expressed by Formula (I), a preparation method thereof, a pharmaceutical salt, and use thereof as a therapeutic agent, especially as a FGFR inhibitor. Each substituent in Formula (I) has identical definition as specified in the specification. 

Substituted pyrazoles as inhibitors of fibroblast growth factor receptor

Growing community of inventors

Taizhou, China

Hua Bai